SEC 13F Intelligence

Managers / Q4 2025 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$706M
Q4 2025
Positions
55
Filings on Record
15
2019–present window
Filed
Feb 17, 2026
original filing

Summary

Artia Global Partners LP reported $706M in U.S.-listed holdings across 55 positions for Q4 2025.

Its largest position, IM8N, represents 16.8% of the portfolio.

Compared with Q3 2025, the fund opened 19 new positions and exited 17.

Portfolio Metrics

Turnover
+28.3%
vs prior filed quarter
Top-10 Concentration
+63.8%
share of reported value
Largest Position
+16.8%
Insmed
New / Exited
19 / 17
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 66.4%ADR: 22.3%Other: 7.1%ETP: 4.3%
  • Common Stock · 66.4% · $469M
  • ADR · 22.3% · $157M
  • Other · 7.1% · $50M
  • ETP · 4.3% · $30M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CDTXCIDARA THERAPEUTICS INCNEW+70.8K70.8K+$16M$16M
VTYXUSDVENTYX BIOSCIENCES INCNEW+696.0K696.0K+$6M$6M
PVLAPALVELLA THERAPEUTICS INC NENEW+59.2K59.2K+$6M$6M
SIONSIONNA THERAPEUTICS INCNEW+119.7K119.7K+$5M$5M
PALIPALISADE BIO INCNEW+1.99M1.99M+$5M$5M
PROKPROKIDNEY CORPNEW+1.84M1.84M+$4M$4M
BLTEBELITE BIO INCNEW+18.0K18.0K+$3M$3M
ROIVANT SCIENCES LTDNEW+129.8K129.8K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

45 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IM8NINSMED INChistory →COM PAR $.0116.82%$119M682.2K
2ABVXABIVAX SAhistory →SPONSORED ADS11.48%$81M600.7K
3ARGXARGENX SEhistory →SPONSORED ADR7.71%$54M64.7K
4LLYELI LILLY & COhistory →COM7.69%$54M50.5K
5VKTXVIKING THERAPEUTICS INChistory →COM3.59%$25M719.4K
6TRVITREVI THERAPEUTICS INChistory →COM3.57%$25M2.01M
7SLNOEURSOLENO THERAPEUTICS INChistory →COM3.50%$25M533.7K
8PROSHARES TR IIULTRA GOLD3.48%$25M442.1K
9UNIQURE NVSHS3.47%$24M1.02M
10NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES2.50%$18M503.9K
11AZNNASTRAZENECA PLChistory →SPONSORED ADR2.48%$18M190.8K
12CDTXCIDARA THERAPEUTICS INChistory →COM NEW2.22%$16M70.8K
13EYPTEYEPOINT PHARMACEUTICALS INChistory →COM NEW1.99%$14M767.1K
14ISIIONIS PHARMACEUTICALS INChistory →COM1.62%$11M144.4K
15DNTHDIANTHUS THERAPEUTICS INChistory →COM1.20%$8M205.1K
16RVMDREVOLUTION MEDICINES INChistory →COM1.18%$8M104.2K
17DGXQUEST DIAGNOSTICS INChistory →COM1.00%$7M40.8K
18ALNYALNYLAM PHARMACEUTICALS INCCOM0.98%$7M17.4K
19VTYXUSDVENTYX BIOSCIENCES INCCOM0.89%$6M696.0K
20PVLAPALVELLA THERAPEUTICS INC NECOM0.88%$6M59.2K
21MLYSMINERALYS THERAPEUTICS INCCOM0.71%$5M137.8K
22SIONSIONNA THERAPEUTICS INCCOM0.70%$5M119.7K
23PALIPALISADE BIO INCCOM0.66%$5M1.99M
24RNAGBPAVIDITY BIOSCIENCES INCCOM0.61%$4M60.1K
25SRRKSCHOLAR ROCK HLDG CORPCOM0.60%$4M96.3K
26RAPPRAPPORT THERAPEUTICS INCCOM0.60%$4M138.5K
27PROKPROKIDNEY CORPSHS CL A0.58%$4M1.84M
28ASCENDIS PHARMA A/SSPONSORED ADR0.54%$4M17.7K
29ABBVABBVIE INCCOM0.47%$3M14.5K
30BLTEBELITE BIO INCSPONSORED ADS0.41%$3M18.0K
31ROIVANT SCIENCES LTDSHS0.40%$3M129.8K
32TVTXTRAVERE THERAPEUTICS INCCOM0.38%$3M70.7K
33DRUGBRIGHT MINDS BIOSCIENCES INCCOM NEW0.37%$3M33.4K
34UTHUNITED THERAPEUTICS CORP DELCOM0.35%$2M5.0K
35PTGXPROTAGONIST THERAPEUTICS INCCOM0.28%$2M23.0K
36UPBUPSTREAM BIO INCCOM0.26%$2M68.7K
37XENEXENON PHARMACEUTICALS INCCOM0.25%$2M40.0K
38OCULOCULAR THERAPEUTIX INCCOM0.24%$2M141.1K
39BBIOBRIDGEBIO PHARMA INCCOM0.22%$2M20.4K
40BTSGBRIGHTSPRING HEALTH SVCS INCCOM0.22%$2M41.6K
41PEPGPEPGEN INCCOM0.19%$1M205.3K
42CELCCELCUITY INCCOM0.18%$1M12.9K
43KINIKSA PHARMACEUTICALS INTLORD SHS CL A0.17%$1M29.2K
44NUVLNUVALENT INCCOM0.12%$814,7798.1K
45AVTXAVALO THERAPEUTICS INCCOM NEW0.11%$754,91141.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.